Document is current
Any future updates will be listed below
-
Authors
Popat, Sanjay https://orcid.org/0000-0003-2087-4963
Januszewski, Adam
O’Brien, Mary
Ahmad, Tanya
Lewanski, Conrad
Dernedde, Ulrike
Jankowska, Petra
Mulatero, Clive
Shah, Riyaz
Hicks, Jonathan
Geldart, Tom
Cominos, Mathilda
Gray, Gill
Spicer, James https://orcid.org/0000-0003-3732-8491
Bell, Karen
Roitt, Simon
Morris, Clive
Ngai, Yenting
Hughes, Laura
Hackshaw, Allan https://orcid.org/0000-0002-5570-5070
Wilson, William
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim (Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992, Timely BIBW2992)
- License Information
-
More Information
Article History
Received: 21 June 2024
Revised: 30 October 2024
Accepted: 31 October 2024
First Online: 5 December 2024
Competing interests
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Prof Popat’s has consulting /advisory Role with Amgen, AstraZeneca (AZ), Bayer, Blueprint, Bristol Myers Squibb (BMS), Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmithKline (GSK), Guardant Health, Incyte, Janssen, Lilly, Merck Serono, Merck Sharp & Dohme (MSD), Novartis, Roche, Takeda, Pfizer, Seattle Genetics, Turning Point Therapeutics & EQRx. He has received payment/Honoraria from AstraZeneca, Bayer, Guardant Health, Janssen, Merck Serono, Roche & Takeda. He has provided expert testimony to Roche, Merck Serono. He has received meeting attendance support from Janssen & Roche. He has a leadership / fiduciary Role with the British Thoracic Oncology Group (BTOG), ALK Positive UK, Lung Cancer Europe, Ruth Strauss Foundation, Mesothelioma Applied Research Foundation & ETOP-IBCSG Partners Foundation Board. Dr Januszewski has received grant/holds contracts with Gilead & Roche. He has received teaching payments from AZ, Johnson and Johnson, Roche, Pfizer, MSD & Bayer. He has received meeting attendance support from Johnson & Johnson Pharmaceuticals & Roche Pharmaceuticals. He has an advisory role with BMS, AZ, Pfizer & MSD. He has a leadership/fiduciary role with BTOG. Dr Ahmad has received speaker payment from AZ. She has received payment for an advisory project from Roche and meeting attendance support from Takeda. Dr Shah has an advisory role with BI. He has received meeting attendance support from BI. He has a leadership / fiduciary role with BTOG & EGFR + UK. Dr Geldart has received honoraria from Merck and meeting attendance support from BMS. Prof Spicer has consulting compensation to author’s employer from AZ, BMS, GSK & RS Oncology; Advisory Board fees. He has an advisory role with CHM Cancer Vaccines Expert Working Group & CHM Expert Advisory Group on Oncology & Haematology. He has a leadership /fiduciary role with BTOG & Experimental Cancer Medicine Centres. He has stock/stock Options with Avacta & Epsiolgen. He has received reimbursements for treatment of trial patients from Achilles, BergenBio, BMS, Gilead, IO Biotech, Iovance, MSD, Roche, RS Oncology, Starpharma & Trizell. Dr Roitt has limited prior shares with Inivata. Dr Mulatero has stocks with Inivata. All remaining authors had no conflicts of interest to declare.
: The TIMELY trial was approved by the Scotland A Research Ethics Committee. Written informed consent was obtained from all patients. The study was performed in accordance with the Declaration of Helsinki.
